news | MaaT Pharma

MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients

mrossettiFebruary 6, 2019

MaaT Pharma Announces Positive DSMB Safety Review and Continuation of its Phase II HERACLES Study in Acute GvHD

Independent Data Safety Monitoring Board (DSMB) recommends to continue HERACLES study without modification. Lyon, France,…

mrossettiFebruary 5, 2019

No Guts, No Glory: How Microbiome Research is Changing Medicine

mrossettiJanuary 23, 2019

Gut bacteria could combat obesity and depression

mrossettiJanuary 17, 2019

ASH readout a curtain raiser for Maat Pharma’s main act

mrossettiDecember 6, 2018

Microbiome Therapy Shows Early Promise in Cancer Patients

mrossettiDecember 5, 2018

The Odyssee study: Results of a prospective multicenter trial – ASH 2018

mrossettiDecember 2, 2018

MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients at the ASH 2018 Annual Meeting

Data show achievement of primary endpoint, demonstration of functional microbiota restoration, inflammation reduction and positive…

mrossettiDecember 2, 2018

le Magazine de la Santé : Lutter contre les complications des traitements contre la Leucémie grâce à nos médicaments Microbiote !

Découvrez comment MaaT Pharma restaure les fonctions du Microbiote Intestinal de patients traités par Chimiothérapie et…

mrossettiNovember 29, 2018

Feedback from BIO Europe 2018 (Copenhagen) – What’s new in the Microbiome Industry ? – Labiotech.eu

mrossettiNovember 28, 2018

NextPrevious »